No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease

Kidney International

Volumn 84, Issue 3, 2013, Pages 555-561

  Chan, Kevin E ^a,b   Thadhani, Ravi I ^b   Maddux, Franklin W ^a  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

anticoagulation; dialysis; thromboprophylaxis

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; CLOPIDOGREL; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT;

ABDOMINAL BLEEDING; ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CONTUSION; DEATH; DEEP VEIN THROMBOSIS; DRUG ACCUMULATION; DRUG APPROVAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG SAFETY; DRUG USE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LUNG EMBOLISM; LUNG HEMORRHAGE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL MODEL; THROMBOSIS PREVENTION; UNITED STATES; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; ENOXAPARIN; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84883445752     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.152     Document Type: Article

References (31)

1. Aguilar D, Goldhaber SZ. Clinical uses of low-molecular-weight heparins. Chest 1999; 115: 1418-1423.
2. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
3. Bhandari M, Hirsh J, Weitz JI et al. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 1998; 80: 413-417.
4. Guillet B, Simon N, Sampol JJ et al. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant 2003; 18: 2348-2353.
5. Cadroy Y, Pourrat J, Baladre MF et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991; 63: 385.
6. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203S.
7. Wein L, Wein S, Haas SJ et al. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: A meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1476-1486.
8. Turnbull JE. Getting the farm out of pharma for heparin production. Science 2011; 334: 462-463.
9. Andersson LO, Barrowcliffe TW, Holmer E et al. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 1979; 15: 531-541.
10. Johnson EA, Mulloy B. The molecular-weight range of mucosal-heparin preparations. Carbohydr Res 1976; 51: 119-127.
11. Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost 1990; 16(Suppl): 12-18.
12. Phung OJ, Kahn SR, Cook DJ et al. Dosing frequency of unfractionated heparin thromboprophylaxis: A meta-analysis. Chest 2011; 140: 374-381.
13. Becker RC, Spencer FA, Gibson M et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002; 143: 753-759.
14. Chow SL, Zammit K, West K et al. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003; 43: 586-590.
15. Alikhan R, Cohen AT. Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Cochrane Database Syst Rev 2009; 8: CD003747.
16. Hoffmann P, Keller F. Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: A meta-analysis. Eur J Clin Pharmacol 2012; 68: 757-765.
17. Tsai TT, Maddox TM, Roe MT et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA 2009; 302: 2458-2464.
18. Janssen MJ, van der MJ. The bleeding risk in chronic haemodialysis: Preventive strategies in high-risk patients. Neth J Med 1996; 48: 198-207.
19. Sreedhara R, Itagaki I, Lynn B et al. Defective platelet aggregation in uremia is transiently worsened by hemodialysis. Am J Kidney Dis 1995; 25: 555-563.
20. Brophy DF, Martin EJ, Best AM et al. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction. J Thromb Haemost 2004; 2: 1299-1304.
21. Brophy DF, Martin EJ, Gehr TW et al. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. Am J Kidney Dis 2004; 44: 270-277.
22. Chan KE, Lazarus JM, Thadhani R et al. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 2009; 20: 872-881.
23. Chan KE, Lazarus JM, Thadhani R et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20: 2223-2233.
24. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
25. Decousus H, Tapson VF, Bergmann JF et al. Factors at admission associated with bleeding risk in medical patients: Findings from the IMPROVE investigators. Chest 2011; 139: 69-79.
26. Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
27. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. National Institutes of Health. Obes Res 1998; 6(Suppl 2): 51S-209S.
28. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: Non-inferiority clinical trials. March 2010.
29. Kaul S, Diamond GA. Good enough: A primer on the analysis and interpretation of noninferiority trials. Ann Intern Med 2006; 145: 62-69.
30. Tunes da SG, Logan BR, Klein JP. Methods for equivalence and noninferiority testing. Biol Blood Marrow Transplant 2009; 15: 120-127.
31. Lagakos SW. The challenge of subgroup analyses-reporting without distorting. N Engl J Med 2006; 354: 1667-1669.